Aspen Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Durban South Africa (1850)
Status: No NME R&D (1850)

Organization Overview

First Clinical Trial
2013
NCT01828697
First Marketed Drug
1954
busulfan (Myleran)
First NDA Approval
1954
busulfan (Myleran)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ASPEN | ASPEN GLOBAL | ASPEN GLOBAL INC | Aspen Global Incorporated | Aspen Pharma

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Embolism (Phase 4)

Injection Site Reaction (Phase 4)

Pulmonary Embolism (Phase 4)

Thrombocytopenia (Phase 3)

Thrombosis (Phase 4)

Venous Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 8